News
CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the EMA has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the
VFMCRP announces U.S. Court upholds validity of Velphoro® patent
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the U.S. District Court for the District of Delaware issued a judgment in VFMCRP’s favor regarding U.S. patent no. 9,561,251
Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19
Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19
Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville
Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. announce tentative settlement of pending litigation
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. announce tentative settlement of pending litigation
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic
Ad-hoc announcement pursuant to article 53 Listing Rules, SIX Exchange 19 August 2022
Ad-hoc announcement pursuant to article 53 Listing Rules, SIX Exchange
19 August 2022
Sonova to accelerate expansion of direct consumer access in Chinese market with acquisition of leading network of clinics
Sonova to accelerate expansion of direct consumer access in Chinese market with acquisition of leading network of clinics
u-blox AG: u-blox reports first half 2022 financial results
u-blox AG: u-blox reports first half 2022 financial results
PSP Swiss Property with a successful H1 2022. Improved ebitda guidance.
PSP Swiss Property with a successful H1 2022.
Improved ebitda guidance.
mobilezone Group achieves another record result in the first half of 2022
mobilezone Group achieves another record result in the first half of 2022
Highlight Event and Entertainment AG records positive sales performance in first half of 2022
Highlight Event and Entertainment AG records positive sales performance in first half of 2022
DGAP-News: Significantly positive sales performance at the Highlight Group
DGAP-News: Significantly positive sales performance at the Highlight Group
Tavneos® (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA)
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) is pleased to announce that England’s National Institute for Health and Care Excellence (NICE) has recommended Tavneos® in combination with a
Emmi grows in line with strategic priorities with slightly lower profitability
Emmi grows in line with strategic priorities with slightly lower profitability
CREALOGIX narrows its focus and spins off the digital learning business
CREALOGIX narrows its focus and spins off the digital learning business
Orascom Development Holding AG: Remarkably strong top-line and bottom-line results with total revenues up 19.8% to CHF 270.5 million and net profit up 298.1% to CHF 20.7 million during 1H 2022.
Orascom Development Holding AG: Remarkably strong top-line and bottom-line results with total revenues up 19.8% to CHF 270.5 million and net profit up 298.1% to CHF 20.7 million during 1H 2022.
Swiss Life increases its fee result by 17% in the first half of 2022 and reports higher profit from operations and net profit
Swiss Life increases its fee result by 17% in the first half of 2022 and reports higher profit from operations and net profit
Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access
Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access
Gurit reports net sales of CHF 234.8 million in the first half of 2022
Gurit reports net sales of CHF 234.8 million in the first half of 2022
Komax receives numerous orders and increases profitability significantly
Komax receives numerous orders and increases profitability significantly